Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of dasatinib to reduce HIV-1 reservoir and immune activation in virally suppressed adults with HIV
2025-524363-20-01Phase 2Authorised
- Sponsor
- Instituto de Salud Carlos III
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Dasatinib arm with Placebo arm (2 arms). Primary endpoint: Primary: Changes in lymphocyte subsets and activation/exhaustion markers. Planned start Jun 2026; status: authorised.
02
Drugs
dasatinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2025-524363-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524363-20-01.